Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 66

Sort by

Sort Order Select

Journal Articles

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Alex F. Herrera, MD, Jasmine Zain, MD, Kerry J Savage, BSc, MD MSc, Tatyana A. Feldman, MD, Jonathan E Brammer, MD, Lu Chen, PhD, Leslie L. Popplewell, MD FRCPA, Lihua E Budde, MD PhD, Lacolle Peters, Yaira Kurtzman, Stephen J Forman, MD, Steven Rosen, MD, Larry W Kwak, MD PhD, Swaminathan P. Iyer, MD

Blood (2019) 134 (Supplement_1): 4023.

https://doi.org/10.1182/blood-2019-123166

Published: 2019

Journal Articles

Outcomes and Side Effect Profile of Ponatinib in Treatment of Chronic Myeloid Leukemia (CML): A Retrospective Single-Center Experience

Onyee Chan, MD, Chetasi Talati, MD, Leidy Isenalumhe, MD, Michael Fradley, MD, Samantha Shams, MD, Javier Pinilla Ibarz, MD, Kendra L. Sweet, MD

Blood (2018) 132 (Supplement 1): 4259.

https://doi.org/10.1182/blood-2018-99-115660

Published: 2018

Journal Articles

Evaluation of Treg and Memory T Cell Profiles, Post-ASCT with Early Combination Nivolumab/Ipilimumab Therapy, in Patients with Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL)

Dante B. Descalzi-Montoya, PhD, Zheng Yang, MS, Kira Goldgirsh, MS, Rena Feinman, PhD, Stacey L. Fanning, PhD, David H. Vesole, MD PhD, Pashna N. Munshi, MD, Michael B Atkins, MD, Scott D. Rowley, MD, Noa Biran, MD, David S Siegel, MD PhD, Andre Goy, MD, Tatyana A. Feldman, MD, Lori A. Leslie, MD, Michele L. Donato, MD, Alan P Skarbnik, MD, Andrew L. Pecora, MD, Robert Korngold, PhD

Blood (2018) 132 (Supplement 1): 3421.

https://doi.org/10.1182/blood-2018-99-120240

Published: 2018

Journal Articles

Quantification of Schistocytes from the Peripheral Blood Smear in Thrombotic Thrombocytopenic Purpura (TTP) Compared to Non-TTP Thrombocytopenic Hospitalized Patients

Timothy E. O'Brien, MD, Lynda Bowman, BS, Augustine Hong, Krishna Goparaju, MD BA

Blood (2018) 132 (Supplement 1): 4983.

https://doi.org/10.1182/blood-2018-99-114159

Published: 2018

Journal Articles

Patient with Myeloma Who Develops Thrombotic Microangiopathy without Hemolysis

Juliana Alvarez Argote, MD

Blood (2018) 132 (Supplement 1): 5661.

https://doi.org/10.1182/blood-2018-99-117095

Published: 2018

Journal Articles

Incidence of Neutropenic Fever at a Safety Net Hospital in Cancer Chemotherapy Patients Receiving Prophylactic Pegfilgrastim Manual Injection Compared to the on-Body Auto-Injector

Atin Jindal, MD, Jan Kover, BPharm, Vanja Raduka, PharmD, R.Ph, Timothy E. O'Brien, MD

Blood (2018) 132 (Supplement 1): 4709.

https://doi.org/10.1182/blood-2018-99-114282

Published: 2018

Journal Articles

Does Venous Thromboembolism Prophylaxis Policy Have Any Impact on Clot Risk Reduction in Hospitalized Solid Tumor Patients at Princess Margaret Cancer Centre: A Longitudinal Study?

Anna Xu, Tian Wang, Eshetu G Atenafu, M.Sc., P.Stat, Hassan Sibai, MBBS, Arjun Datt Law, MBBS, MD DM, Kelsey Japs, Joseph Samuel, andreW. Stessman, Triyu Vather, Helen Vu, Jack Seki, PharmD, Jennifer Carter

Blood (2017) 130 (Supplement 1): 5651.

https://doi.org/10.1182/blood.V130.Suppl_1.5651.5651

Published: 2017

Journal Articles

Emerging Immune Targets for Treatment of Multiple Myeloma

Atif Sohail, MD MBBS, Adeela Mushtaq, MD, Ahmad Iftikhar, MD, Azka Latif, MD, Vikas Kapoor, MD, Faiza Hassan Warraich, MD, Sami Ullah Warraich, MBBS, Mirza Zeeshan Baig, MD, Ali McBride, PharmD,MS, Faiz Anwer, MD

Blood (2017) 130 (Supplement 1): 5429.

https://doi.org/10.1182/blood.V130.Suppl_1.5429.5429

Published: 2017

Journal Articles

Innate Immune Activation Via TLR9 May Enhance Antibody Formation Against Factors VIII and IX in Protein and Gene Therapy

Roland W Herzog, PhD, Alexandra Sherman, DVM, Brad E. Hoffman, PhD

Blood (2017) 130 (Supplement 1): 3651.

https://doi.org/10.1182/blood.V130.Suppl_1.3651.3651

Published: 2017

Journal Articles

Hydroxyurea Mucocutaneous Toxicity: A Prospective Cohort Study of 110 ET and PV Patients from a Single Institution

Carlos Besses Raebel, MD PhD

Blood (2017) 130 (Supplement 1): 4208.

https://doi.org/10.1182/blood.V130.Suppl_1.4208.4208

Published: 2017

Journal Articles

DA-EPOCH-R Is an Effective Regimen in High Grade B-Cell Lymphoma Defined By Cell-of-Origin, Karyotype and BCL2 / MYC / BCL6 Status and Expression

Blood (2016) 128 (22): 1754.

https://doi.org/10.1182/blood.V128.22.1754.1754

Published: 2016

Journal Articles

Detecting Accumulated Somatic Mutations in Healthy Aged Female Myeloid Cells

Jack M. Lionberger, MD PhD, Ninder K. Panesar, PhD, Bharat Panuganti, Ahmad Rajeh, Carl E. Freter, MD PhD

Blood (2016) 128 (22): 5045.

https://doi.org/10.1182/blood.V128.22.5045.5045

Published: 2016

Journal Articles

Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma

John H. Chen, Daniel J. Lenihan, MD, Sharon E. Phillips, MSPH, Madan H. Jagasia, Stacey A. Goodman, MD MS, Adetola A. Kassim, MD MS, Shelton L. Lacy, Kevin T. McDonagh, Javid J. Moslehi, MD, Tarsheen K. Sethi, MD MS, David A. Slosky, Oluchi C. Ukaegbu, MD, Robert F. Cornell

Blood (2015) 126 (23): 5363.

https://doi.org/10.1182/blood.V126.23.5363.5363

Published: 2015

Journal Articles

Exposure to New Therapies and Treatment Delay in Multiple Myeloma: Experience from a Safety Net Hospital

Timothy O'Brien, MD, Barbara Ruda, RN, Andrew Cluckey, MDcal student

Blood (2015) 126 (23): 5615.

https://doi.org/10.1182/blood.V126.23.5615.5615

Published: 2015

Journal Articles

Multicenter Phase 1b Dose-Escalation Study of Ibrutinib and Lenalidomide Combined with Dose-Adjusted EPOCH-R in Patients with Relapsed/Refractory DLBCL

Wyndham H. Wilson, MD PhD, Leslie L. Popplewell, MD, Tycel Phillips, MD, Amy S. Kimball, MD PhD, Saurabh Chhabra, MD, Jerry Ping, PhD, Jutta Neuenburg, MD, Nora Cavazos, MD, Louis M Staudt, MD, Sven de Vos, MD PhD

Blood (2015) 126 (23): 1527.

https://doi.org/10.1182/blood.V126.23.1527.1527

Published: 2015

Journal Articles

Differentially Expressed Genes and Pathways in Endothelial Cells Exposed to Hemin or Plasma from Patients with Sickle Cell Disease: A Meta-Analysis of Gene Expression Studies

Maiara M L Fiusa, Marina Pereira Colella, MD PhD, Joyce M Annichino-Bizzacchi, MD PhD, Loredana Nilkenes, Bidossessi W Hounpke, Sara T O Saad, MD PhD, Fernando Ferreira Costa, MD PhD, Erich Vinicius De Paula, MD PhD

Blood (2014) 124 (21): 4018.

https://doi.org/10.1182/blood.V124.21.4018.4018

Published: 2014

Journal Articles

Plasmablastic Lymphoma Is Curable The HAART Era. A 10 Year Retrospective By The AIDS Malignancy Consortium (AMC)

Ariela Noy, MD, Amy Chadburn, M.D., Shelly Y. Lensing, MS, Page Moore

Blood (2013) 122 (21): 1801.

https://doi.org/10.1182/blood.V122.21.1801.1801

Published: 2013

Journal Articles

A Phase I Dose Escalation Study Of TGR-1202, a Novel PI3K-δ Inhibitor, For Patients With Relapsed Or Refractory Hematologic Malignancies

Michael Savona, MD, Martin Gutierrez, MD, Mark Lanasa, MD, PhD, Changchun Deng, MD, PhD, John Kuhn, PharmD, Lauren Sade, Hari Miskin, MS, Peter Sportelli, Swaroop Vakkalanka, PhD, Manish Patel, MD

Blood (2013) 122 (21): 4373.

https://doi.org/10.1182/blood.V122.21.4373.4373

Published: 2013

Journal Articles

ARL-IPI - A New Prognostic Score for AIDS-Related Lymphomas in the Rituximab Era

Stefan K Barta, MD, MS, MRCP, Xiaonan Xue, Ph.D., Dan Wang, MS, Jeannette Y Lee, Ph.D., Lawrence D. Kaplan, MD, Josep-Maria Ribera, MD, PhD, Albert Oriol, Olga Garcia, Mireia Morgades, Michele Spina, MD, Umberto Tirelli, MD, Francois Boue, MD, PhD, Wyndham H. Wilson, MD, PhD, Christoph Wyen, MD, Kieron Dunleavy, MD, Joseph A Sparano, MD

Blood (2012) 120 (21): 1564.

https://doi.org/10.1182/blood.V120.21.1564.1564

Published: 2012

Journal Articles

Favourable Outcome in Infants with Acute Myeloid Leukemia Treated with the AIEOP AML 2002/01 Protocol

Riccardo Masetti, MD, Martina Pigazzi, PhD, Andrea Pession, Prof, MD, Carmelo Rizzari, MD, PhD, Nicola Santoro, Luca lo Nigro, Matteo Luciani, Giuseppe Menna, Roberto Rondelli, Giuseppe Basso, Franco Locatelli

Blood (2012) 120 (21): 3585.

https://doi.org/10.1182/blood.V120.21.3585.3585

Published: 2012

NARROW

Preliminary Results from a Phase 2 Trial of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed By BV Consolidation in Patients with CD30-Positive Peripheral T-Cell Lymphomas

Outcomes and Side Effect Profile of Ponatinib in Treatment of Chronic Myeloid Leukemia (CML): A Retrospective Single-Center Experience

Evaluation of Treg and Memory T Cell Profiles, Post-ASCT with Early Combination Nivolumab/Ipilimumab Therapy, in Patients with Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL)

Quantification of Schistocytes from the Peripheral Blood Smear in Thrombotic Thrombocytopenic Purpura (TTP) Compared to Non-TTP Thrombocytopenic Hospitalized Patients

Patient with Myeloma Who Develops Thrombotic Microangiopathy without Hemolysis

Incidence of Neutropenic Fever at a Safety Net Hospital in Cancer Chemotherapy Patients Receiving Prophylactic Pegfilgrastim Manual Injection Compared to the on-Body Auto-Injector

Does Venous Thromboembolism Prophylaxis Policy Have Any Impact on Clot Risk Reduction in Hospitalized Solid Tumor Patients at Princess Margaret Cancer Centre: A Longitudinal Study?

Emerging Immune Targets for Treatment of Multiple Myeloma

Innate Immune Activation Via TLR9 May Enhance Antibody Formation Against Factors VIII and IX in Protein and Gene Therapy

Hydroxyurea Mucocutaneous Toxicity: A Prospective Cohort Study of 110 ET and PV Patients from a Single Institution

DA-EPOCH-R Is an Effective Regimen in High Grade B-Cell Lymphoma Defined By Cell-of-Origin, Karyotype and BCL2 / MYC / BCL6 Status and Expression

Detecting Accumulated Somatic Mutations in Healthy Aged Female Myeloid Cells

Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma

Exposure to New Therapies and Treatment Delay in Multiple Myeloma: Experience from a Safety Net Hospital

Multicenter Phase 1b Dose-Escalation Study of Ibrutinib and Lenalidomide Combined with Dose-Adjusted EPOCH-R in Patients with Relapsed/Refractory DLBCL

Differentially Expressed Genes and Pathways in Endothelial Cells Exposed to Hemin or Plasma from Patients with Sickle Cell Disease: A Meta-Analysis of Gene Expression Studies

Plasmablastic Lymphoma Is Curable The HAART Era. A 10 Year Retrospective By The AIDS Malignancy Consortium (AMC)

A Phase I Dose Escalation Study Of TGR-1202, a Novel PI3K-δ Inhibitor, For Patients With Relapsed Or Refractory Hematologic Malignancies

ARL-IPI - A New Prognostic Score for AIDS-Related Lymphomas in the Rituximab Era

Favourable Outcome in Infants with Acute Myeloid Leukemia Treated with the AIEOP AML 2002/01 Protocol

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only